LungArchives
NAT10-mediated lipid metabolic reprogramming drives EGFR-TKI resistance in non-small cell lung cancer via ac4C-dependent mRNA stabilization
Lung 8 min.
Non-small cell lung cancer (NSCLC) is a highly significant contributor to cancer-related mortality worldwide, accounting for a substantial proportion of all cancer deaths [1, 2]. Although targeted treatments like epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated...
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies
Lung 13 min.
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide [1]. It encompasses several histological types, including adenocarcinoma (LUAD), squamous cell carcinoma (LUSC), large cell carcinoma and rarer types [2]. NSCLC has a high rate of somatic mutations [3], contributing...
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer
Lung 5 min.
Pembrolizumab administered by intravenous (IV) infusion was first approved in 2014 for treatment of advanced melanoma and has since gained regulatory approval in many countries for multiple tumor types and disease stages, including metastatic non-small cell lung cancer (mNSCLC) [1, 2]. Pembrolizumab...
Three-dimensional analysis to predict recurrence of pure-solid non-small cell lung cancer after segmentectomy
Lung 4 min.
The Japan Clinical Oncology Group 0802 (JCOG 0802) recently conducted a pivotal randomized controlled trial [1] that compared the non-small cell lung cancer (NSCLC) survival rates of lobectomies and segmentectomies for tumors less than 2 cm in diameter. These findings highlighted the value of the segmentectomy...
